Open AccessVascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1)
Author(s) -
Christopher A. Mecoli,
Jamie Perin,
Jennifer E. Van Eyk,
Jie Zhu,
Qin Fu,
Andrew G. Allmon,
Youlan Rao,
Scott L. Zeger,
Fredrick M. Wigley,
Laura K. Hummers
Publication year - 2019
Publication title -
clinical rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.835
H-Index - 82
eISSN - 1434-9949
pISSN - 0770-3198
DOI - 10.1007/s10067-019-04863-0
Subject(s) - treprostinil , medicine , rheumatology , randomized controlled trial , scleroderma (fungus) , cardiology , physical therapy , pathology , pulmonary hypertension , inoculation
Although there is abundant evidence of vascular perturbation from studies of peripheral blood in systemic sclerosis (SSc), there are few data about the ability to use biomarkers of vascular injury and growth factors to predict vascular outcomes and response to therapy. We sought to explore the association between candidate vascular biomarkers and digital ulcerations (DU) in a clinical trial context.